-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145

Benzinga·07/27/2026 11:18:42
Listen to the news
JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight rating and announces Price Target of $145.